Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

156.84 -1.41 (-0.89%)

Streaming Delayed Price Updated: 2:18 PM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing ↗

March 04, 2025

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.

Via Stocktwits

Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook ↗

March 03, 2025

CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024.

Via Stocktwits

Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week ↗

March 03, 2025

Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year.

Via Stocktwits

Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print ↗

February 27, 2025

The company plans to unveil details at its virtual R&D Day on March 13.

Via Stocktwits

MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’ ↗

February 27, 2025

The company significantly reduced its debt principal by $236 million, leaving just $36 million in remaining convertible debt, and ended 2024 with $203 million in cash, cash equivalents, and...

Via Stocktwits

Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally ↗

February 26, 2025

Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.

Via Stocktwits

NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst ↗

February 24, 2025

Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH.

Via Benzinga

Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism ↗

February 20, 2025

Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.

Via Stocktwits

SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect ↗

February 20, 2025

Recent investor enthusiasm has been fueled by reports that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks.

Via Stocktwits

Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports ↗

February 19, 2025

Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors.

Via Benzinga

Biotech Stocks Had A Good Week Despite Crosscurrents ↗

February 18, 2025

It’s too early to account for the rally but in general one can say that there is a lot of speculation from both the retail side and hedge funds.

Via Talk Markets

Topics ETFs Stocks / Equities

Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug ↗

February 11, 2025

The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter.

Via Stocktwits

Healthcare And Biotech Playbook As Disruption Gathers Force ↗

February 10, 2025

The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82.

Via Talk Markets

Topics ETFs Stocks / Equities

Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets ↗

February 10, 2025

Reuters reported that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company.

Via Stocktwits

Viking Therapeutics Stock Down Over 20% In 2025: Retail Traders Predict Where It Could End The Year ↗

February 07, 2025

In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735 and a Phase 1 trial of an oral tablet form of VK2735 to treat obesity.

Via Stocktwits

Small- To Mid-Cap Biotech Trades Poised For Gains ↗

February 01, 2025

On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these...

Via Talk Markets

Topics ETFs Stocks / Equities

Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail ↗

January 27, 2025

The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.

Via Stocktwits

Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens ↗

January 27, 2025

The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.

Via Stocktwits

Akero Stock Hits Over 18-Month High On MASH Trial Data: Citi Lauds ‘Best-Case Scenario,’ Retail Exuberant ↗

January 27, 2025

The analyst highlighted that major pharmaceutical companies are already pursuing GLP-1-based therapies for MASH, but he believes efruxifermin could complement these treatments.

Via Stocktwits

Moderna Retains Retail Support With European COVID-19 Vaccine Tender Win, Stock Hits 2-Week High ↗

January 24, 2025

The agreement, which spans up to four years, allows 17 participating countries access to Moderna’s vaccine in various formats.

Via Stocktwits

Healthcare And Biotech Stocks Lag The Market Again ↗

January 20, 2025

Biotech stocks got little help from the JPM Conference despite some recovery to the general market.

Via Talk Markets

Topics Stocks / Equities

'Buy Long Duration Bonds,' Says Bank Of America Strategist: 4 ETFs To Watch As Trump's Deficit Fight Unfolds ↗

January 17, 2025

Investors may be underestimating Trump's potential push for fiscal discipline, making long-term bonds and rate-sensitive sectors attractive bets.

Via Benzinga

Topics Bonds ETFs Government

We Asked Retail How Viking Therapeutics Can Restore Investor Confidence: Majority Say Pursue Buyout Talks ↗

January 15, 2025

Oppenheimer earlier this month listed Viking as one of five biotech companies that could be prime candidates for an "aspirational" takeover.

Via Stocktwits

Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes ↗

January 15, 2025

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

Via Stocktwits

I’m Not Worried About This Pullback ↗

January 08, 2025

Stocks gave back all of Monday’s gains and then some today. Monday’s panic buyers were mercilessly punished for going nuts during the spree.

Via Talk Markets

Topics Cryptocurrencies Stocks / Equities

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies ↗

January 08, 2025

Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.

Via Benzinga

Topics ETFs

Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks ↗

January 06, 2025

The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter.

Via Talk Markets

Topics ETFs Stocks / Equities

No Value In Value? Stock Market (And Sentiment Results) ↗

January 02, 2025

In a year like 2024, it is easy to forget the fact that since 1927 “Value” has outperformed “Growth” by 4.4% per year:

Via Talk Markets

Topics Stocks / Equities

Healthcare And Biotech Stocks Continue Their Slide ↗

December 30, 2024

Biotech shares continued their slide which began in early November and got no help from small caps which also sold off through December.

Via Talk Markets

Topics ETFs Stocks / Equities

Are You Ready To Trade Biotech Stocks At The Cusp Of A Bear Market? ↗

December 23, 2024

It’s not a bear market for biotech yet it just feels that way because recent trends are down and healthcare stocks are not a stabilizing force.

Via Talk Markets

Topics ETFs Stocks / Equities

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.